ASX ANNOUNCEMENT

OTCQX Life Sciences Presentation

Melbourne, Australia; 1 October 2015: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that as part of its OTCQX investor communications, a pre-recorded presentation by Chief Executive Officer Dr Jackie Fairley will be broadcast at VirtualInvestorConferences.com on Thursday, October 1, 2015 at 12.15pm (EDT time). The presentation is part of a special OTCQX Life Sciences virtual Conference.

The presentation will provide an overview of the Company for new investors including recent announcements:

- EU marketing approval for VivaGel® BV; and
- Drug delivery license with AstraZeneca for DEP™ technology.

Interested parties are able to register at www.virtualinvestorconferences.com or at the following link: http://tinyurl.com/101pre . An on-demand archive will be available for 90 days at www.virtualinvestorconferences.com.

A copy of the presentation slides is attached.

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has three core development programs: VivaGel® portfolio, DEP™ drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's lead products are based on VivaGel® (SPL7013, astodrimer sodium), a proprietary dendrimer which has antimicrobial properties. VivaGel® formulated as a water based gel and delivered vaginally now has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and is under clinical development for the prevention of recurrent BV. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries. Inc., (TSE: JP3192800005) to market a value-added, VivaGel® condom. The VivaGel® condom is available for purchase in Australia under Ansell's Lifestyles® Dual Protect™ brand. Ansell manufactures and sells leading condom brands worldwide, including LifeStyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, which is the world's second largest condom market.

In the wider pharmaceutical field, Starpharma has both partnered and internal programs in Drug Delivery. A number of dendrimer-enhanced, or DEP® versions of existing drugs are under development. The most advanced of these is DEP® docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid tumours. In preclinical studies DEP® docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important

cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel). AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound, with potential for follow on compounds directed at a defined family of targets.

In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama (formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®). For more information please visit: www.starpharma.com

FOR FURTHER INFORMATION

Media:
Buchan Consulting
Rebecca Wilson
Mob: +61 417 382 391
rwilson@buchanwe.com.au

Starpharma:
Dr Jackie Fairley, CEO
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.


starpharma
Dr. Jackie Fairley CEO
STARPHARMA HOLDINGS LIMITED
ASX:SPL; OTCQX:SPHRY
Corporate Overview
September/October 2015

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

One of Australia's most innovative technology companies

- **ASX 300 company (ASX:SPL) and US (OTCQX:SPHRY).**
- A **platform technology** with multiple product opportunities across the pharmaceutical, life science and agrochemical industries.
- **De-risked business model**:
  - Portfolio of products based on proprietary polymers (dendrimers) in various stages of development including one product on market, a product recently approved for market entry, and in late stage clinical trials;
  - Developing first-in-class (new) therapies through a highly experienced in-house commercialization team;
  - Established commercial partnerships - with some of the world's leading companies accelerates product development, shares development risk, and transfers development costs;
  - Multiple "shots on goal" due to the versatility and broad applicability of Starpharma's technology.
- **Multiple commercial and product development catalysts expected within next 12 months.**
- **Strong cash position:** Cash balance of A$30.8M (June 2015)

Starpharma headquarters in Melbourne, Australia

One of Australia's most innovative biotechnology companies

Starpharma's portfolio is a mix of internal programs and external commercial partnerships

Starpharma's Dendrimer Platform
>80 granted patents





VivaGel® Portfolio

VivaGel® Condom

Bacterial vaginosis

VivaGel® BV Symptomatic Relief BV

VivaGel® BV BV Prevention

DEP™ Drug Delivery

DEP™ docetaxel

DEP™ oxaliplatin (and others)

Partner Delivery Programs

& other undisclosed Top 10 Pharma companies

Agrochemicals

Priostar® Improved Agrochemicals ie. Glyphosate

Partner Priostar® Programs

>50% Top 10 Ag. companies

Starpharma's Pharmaceutical Development Portfolio

			Res	PC	PhI	PhII	PhIII	Reg.	Mkt
Antimicrobial / Antiviral (SPL7013)	VivaGel® BV	BV Symptomatic Relief							
	VivaGel® BV	BV Prevention of Recurrence							
	VivaGel® Condom	Ansell / Okamoto							
Oncology (Internal)	Drug Delivery	DEP™ docetaxel (various cancers)							
	Drug Delivery	DEP™ oxaliplatin							
	Drug Delivery	Various Oncology DEP™							
Partnered programmes	Drug Delivery -	DEP™ Delivery – oncology, diabetes etc.			AstraZeneca				

Completed

Planned

EU Marketing Approval granted for VivaGel® BV

starpharma

ASX ANNOUNCEMENT

EU Marketing Approval Granted for VivaGel® BV

Melbourne, Australia; 24 September 2015: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has received, overnight, marketing approval in the European Union (EU) for VivaGel® BV for the treatment and rapid relief of bacterial vaginosis (BV) including symptoms.

The approval allows for the marketing of VivaGel® BV in the European Economic Area (EEA), which includes the 28 countries of the EU plus the European Free Trade Association (EFTA) countries, providing access to a population of more than 260 million women. In addition, the EU approval will be used as the basis for obtaining what is expected to be relatively rapid regulatory and marketing approvals for VivaGel® BV in a number of other countries that formally recognise the EU approval.

Bacterial vaginosis is the most common vaginal infection worldwide. It is the most common cause of abnormal vaginal discharge and unpleasant vaginal odour in women and is associated with an increased risk of pre-term births, miscarriage, and transmission and acquisition of STIs, including genital herpes and HIV/AIDS.

- VivaGel® BV gains EU approval for the treatment and rapid relief of BV
- Allows for marketing in 28 EU countries & EFTA countries (population >260m women)
- EU Approval will be used as the basis for obtaining marketing approvals for VivaGel® BV in other countries
- Discussions regarding marketing rights for VivaGel® BV underway with a number of potential commercial partners
- Current market for the management of BV and associated symptoms is estimated to be in excess of US$750 million globally.

- "It was like gone almost overnight"
- "I would definitely use it again."
- "The next day I noticed a huge difference."
- "I would use it….I will use it indefinitely…"

VivaGel® Trial Participants

VivaGel® BV is a unique topical vaginal gel. Its proprietary active is not absorbed and acts locally to suppress the pathogens that cause BV and the associated signs and symptoms.

Starpharma's DEP™ delivery license with AstraZeneca (LON:AZN)

starpharma

ASX ANNOUNCEMENT

Starpharma signs drug delivery license with AstraZeneca

- AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound on signature, and with potential for follow on compounds directed at a defined family of targets.
- Under the agreement Starpharma will receive a signature payment of US$2 million (A$2.9 million), and is also eligible to receive potential development, launch and sales milestones for the first AstraZeneca DEP® product of USD$124 million (A$177 million).
- Subsequent qualifying products successfully developed and commercialised to specified annual sales levels could yield up to USD$93.3 million (A$133 million) in milestone payments per product.
- In summary, signature and milestone payments could total USD$126 million (A$180 million) for the first AstraZeneca DEP® product and up to USD$93.3 million (A$133 million) for each subsequent qualifying product.
- Any AstraZeneca DEP® products would also attract tiered royalties on net sales.
- AstraZeneca will fund all development and commercialisation costs for AstraZeneca DEP® products under the agreement.

- **AZ licensed DEP™ drug delivery platform in the development and commercialisation of a novel, proprietary AZ oncology compound**
- **SPL eligible to receive development, launch and sales milestones for the first AZ DEP™ product of USD$126 million (A$180m) (including a signature payment US$2m)**
- **Licence provides for application of DEP™ to multiple AZ compounds directed at a defined family of targets**
- **Each subsequent qualifying product successfully developed and commercialised could yield USD$93m (A$133m) in milestone payments**
- **Tiered royalties on net sales**
- **AZ will fund all development and commercialisation costs**

"SPL estimates that each product successfully commercialised under this agreement could be worth around US$450m to Starpharma and, depending on the range of indications and degree of commercial success in the market, potentially significantly more"

"We already have a long-standing and successful working relationship with Starpharma. This license agreement will enable us to further harness the DEP™ technology and evaluate its potential across novel molecules within our oncology portfolio."

Dr Susan Galbraith,
Head of the Oncology Innovative Medicines Unit at AstraZeneca

AstraZeneca

starpharma



DEP™ Drug Delivery

Starpharma's DEP™ docetaxel: Multiple benefits

- Docetaxel (Taxotere®) is a blockbuster chemotherapeutic
- **Docetaxel sales: US$3.1B(2012)**
- Docetaxel is used in major cancer types including breast, prostate and lung cancer
- Starpharma's patented DEP™ docetaxel is a nanoparticle formulation with **multiple advantages compared to Taxotere®**
- **DEP™ patents filed will offer coverage to 2032**
- **DEP™ docetaxel Phase 1 Trial in Australia progressing well; promising preliminary findings with very good tolerability**

DEP™ docetaxel vs. Taxotere®

1. Elimination of major dose-limiting side effect (neutropenia)
2. Detergent-free formulation (less toxic)
3. Tumour-targeting (40-70x more)
4. Extended duration (half-life)
5. Improved efficacy (breast, ovarian, prostate)

TAXOTERE® (docetaxel) Injection Concentrate



DEP™ docetaxel preclinical findings:

Multiple advantages - Better efficacy and less toxicity



$T_{1/2}$ and Targeting

	Plasma Half Life (hours)*
DEP™– Docetaxel	39
Taxotere®	0.5

*n = 4 rats per group

DEP™ docetaxel formulation extends plasma t1/2 by >60-fold vs. Taxotere®



DEP™ docetaxel shows preferential uptake into mouse MDA-MB-231 xenograft (45-70 fold)

Safety

DEP™ docetaxel – Polysorbate 80-free and Water soluble

Docetaxel

Starpharma's water soluble DEP™ docetaxel:
- solubility >↑ 20,000x
- polysorbate 80-free



DEP™– Reduction of bone marrow toxicity and DLT's

- Neutrophils levels are expressed as the mean absolute count across all animals (n=6)
- drug (equivalent docetaxel amounts) was administered to Sprague Dawley rats by intravenous injection.

Efficacy



Mouse Xenograft (MDA-MB 231); N= 10/group; p< 0.0001



Mantel-Cox log-rank test - Taxotere® vs DEP™ docetaxel (P=0.007).

Patents filed will offer coverage to 2032

DEP™ docetaxel: Phase 1 Clinical Trial

Encouraging initial clinical data

- Underway at 4 Australian sites* ; Open label study - allowing progressive release of results
- Estimated sample: 25-30 cancer patients (various solid tumours)

Current Status

- DEP™ docetaxel administered every 3-4 weeks (*no steroid pre-treatment required)*
- Patients currently being enrolled in dose escalation phase
- several dosed with multiple cycles (up to 6 cycles)
- dose-level exceeds commonly used Taxotere® dose 75mg/m^2
- > 2/3 recruitment

Interim Findings: DEP™ docetaxel well tolerated *with encouraging anticancer activity*

- ***No neutropenia*** (docetaxel DLT) observed so far (*c.f Taxotere® where published data indicates* ***severe neutropenia*** *will be suffered by* ***75% of patients given 60mg/m^2*** *)*
- *No alopecia/hair loss or vomiting reported*
- A sizable number of patients have exhibited efficacy signals/anticancer activity (one with pancreatic Ca. stable disease over > 20 weeks; prostate, lung, H&N)
- Enhanced Pharmacokinetics demonstrated (longer half-life, higher AUC and lower Cmax)
- Expansion phase to follow at MTD

*Alfred, Austin Health/Olivia Newton John CC, Liverpool and Royal Brisbane & Women's Hospital

DEP™ docetaxel Pharmacokinetics (PK) in humans cf. Taxotere®^

Enhanced PK in humans

1. Extended duration of exposure with DEP™ docetaxel

- DEP™ docetaxel plasma **half-life substantially longer** (~8 x) than Taxotere® (~150x longer in the initial, rapid phases of plasma clearance)

2. Increased extent of exposure with DEP™ docetaxel

- DEP™ docetaxel **drug exposure** or **Area Under the Curve** (AUC) for total docetaxel, **~500-800x greater** than an equivalent dose of docetaxel administered as Taxotere®
- reflects the gradual release of docetaxel (DEP™ docetaxel acts as a 'depot' of docetaxel)

3. Reduced peak drug levels with DEP™ docetaxel

- **Cmax (peak blood level)** of docetaxel is **substantially (~50-100 times) lower for DEP™ docetaxel** than Cmax of an equivalent dose of docetaxel administered as Taxotere®





Example plasma drug levels over time DEP™ docetaxel vs.Taxotere®)

^ *Taxotere® parameters based on published data (Bruno et al, 1996)*

DEP™ docetaxel compared with BIND's docetaxel
Compelling product benefits for DEP™

Aspect	BIND^	DEP™ docetaxel	Starpharma Benefit
Manufacture	complex, self assembled particles; potential for inconsistency b/w batches	Standard chemistry	SPL dendrimer manufacture readily scalable and validated through extensive FDA input
Stability	self loading particle; inherently unstable	Excellent stability	Important for drug approval, storage and subsequent shelf life
Drug loading w/w	10%	25%	SPL delivers higher dose per mg of drug
Particle Size	60-120nm	10-15nm	Smaller particles enter tissues more easily
Tumour concentration of active	10-20x	30-60x	Higher level of docetaxel delivery to tumour SPL - better efficacy & reduced toxicity
Plasma Half life	6-20 hours	>50 hours	Longer duration of effect, less frequent dosing and greater anti cancer effect
Water soluble (detergent free)	No	Yes; solubility ~ 20,000 fold increased	Water soluble; detergent free (see below)
Neutropenia prevented	No	Yes	Avoids risks & need for expensive rescue therapies / GCSF and hospitalisation
Polysorbate used	Yes - cortisone pre-treatment required	No - cortisone pre-treatment is not required	Avoids potentially fatal toxicities with polysorbate-containing formulations

^ *parameters based on published data*

Additional DEP™ candidates

- SPL's dendrimer enhanced product (DEP™) nanoparticle technology
  - ✓ broad applicability, especially in oncology
  - ✓ allows for new patent filings creating proprietary products
- Proof of DEP™ concept for docetaxel, doxorubicin, oxaliplatin, methotrexate, gemcitabine and paclitaxel, proteins (insulin), peptides and Targeted agents (ADCs)
- A number of additional DEP™ candidates from the list below are currently in preclinical testing

Brand	Generic Name	Type of Drug	Innovator Company	2014 Sales / Peak Sales prior to loss of exclusivity (US$ M)
Taxotere	Docetaxel	Cytotoxic	Sanofi Aventis	3,036
Alimta	Pemetrexed	Anti-metabolite	Eli Lilly	2,792
Eloxatin	Oxaliplatin	Cytotoxic	Sanofi Aventis	2,293
Gemzar	Gemcitabine	Anti-metabolite	Eli Lilly	1,720
Camptosar	Irinotecan	Cytotoxic	Pfizer	1,100
Jevtana	Cabazitaxel	Cytotoxic	Sanofi Aventis	363
Kadcyla	Ado-trastuzumab emtansine	ADC	Roche	624
Adcetris	Brentuximab vedotin	ADC	Takeda	395

Targeted DEP™ Conjugates (TDCs)

A new approach to drug conjugate design



More than **20** ADC drug licensing deals in the past 5 years

50% of the top 10 products are antibodies with 2013 sales in excess of **$US38B**

The top 3 oncology products are antibodies with combined sales of **US$20B**

Starpharmas Targeted DEP™ conjugates	
Can use small molecule, whole antibody, antibody fragments or antibody mimetics	✓
Bind with high affinity and specificity	✓
Highly efficacious in cancer model in vivo	✓
Flexible and tailored to suit clinical requirements	✓
Homogeneous	✓
Standard Chemistry yielding consistent, reproducible, stable molecules	✓
Platform already in the clinic and demonstrated to be safe and well tolerated	✓



starpharma

THE WORLD'S FIRST ANTI-VIRAL CONDOM



VivaGel® Portfolio

VivaGel® Condom – World's first antiviral condom

Lifestyles® DUAL PROTECT™ - Available in Australian retail outlets

THE WORLD'S FIRST ANTI-VIRAL CONDOM

Extensive consumer research of the VivaGel® condom^:

- *Confirms strong interest and purchase intent (~90%)*
- Strong consumer interest across genders, ages and relationship status

Percentages shown are the 'top-2-box' scores	TOTAL			18-30 years	31-40 years	41-50 years
Level of interest	85%	88%	82%	87%	86%	82%

"I would buy this product right now if I could….."

"I like the idea of a condom doing more for us than just being a barrier….seems more reassuring to know it's doing extra"

"I would definitely buy this product without a shadow of a doubt….."

VivaGel® Condom Consumer Research

"I think that this product is amazing…... This product is very special and interesting."
"I have rated this product a 5/5 as this is a major breakthrough in the condom market and for world health…"

VivaGel® Condom Consumer Research

DUAL PROTECT™ with VivaGel® : lubricated with VivaGel® which has been shown to inactivate up to 99.9% HIV, HPV and HSV (Herpes) in laboratory studies

^ Formal research conducted in 1800 condom users across USA, Europe, Asia and Sth America

VivaGel® condom: A compelling and differentiated product

- Condom coated with SPL's patented antiviral lubricant (VivaGel®)
- **VivaGel®** shown in laboratory studies to **inactivate up to 99.9% HIV, HPV & Herpes**
- Licensed to Ansell and Okamoto (SPL receives royalties on sales)
- Regulatory Certification received in Japan and Australia, NZ other filings in progress
- Product selling in Australia under Lifestyles® Dual Protect™ brand
- Extensive international consumer research indicates strong consumer interest
- Branded global condom market: $1.1B
- VivaGel® condom patents to 2027

Partner	Market Position/Share	Major Brands
Okamoto Industries (listed on TSE)	• No. 1 in Japan with ~60% Japanese market (the 2nd largest condom mkt. Est. ~US$500M) • Total revenues >US$760M	Skinless® 003®
Ansell Limited ASX:ANN	• No. 2 globally for condom sales ~ 20% global share of branded condom market (~$1.1B)	Lifestyles® SKYN® ZERO® Manix®

Bacterial Vaginosis and VivaGel® BV: Two product opportunities

Bacterial Vaginosis:

- **the most common vaginal infection worldwide**
- **~29% women infected in US; up to 51% in some groups**
- **Recurrent BV an issue in 50-60% of BV sufferers**
- **Current therapies have low cure rates and nasty side effects**
- **No approved products for Recurrent BV (R-BV)**

- *"It was like gone almost overnight"*
- *"I would definitely use it again."*
- *"The next day I noticed a huge difference."*
- *"I would use it….I will use it* indefinitely…"
  - *VivaGel® BV Trial Participants*



Product Proposition:

VivaGel® BV:

- **a <u>non-antibiotic therapy</u>**
- **management of BV symptoms *and***
- **prevention of Recurrent BV**
- **a selective antimicrobial effect for pathogens that cause BV**
- **a local effect and is not systemically absorbed**
- **Large market opportunity for both prevention of recurrent BV and BV Symptomatic Relief**

* Global Data, IMS, various Industry reports

Bacterial Vaginosis and VivaGel® BV: Two product opportunities

VivaGel® BV Indications	Drivers of Value: Significant Market Size	Competitive Advantages	Development and Commercial Progress
Prevention of BV Recurrence (Chronic use)	>US$1B	• Unmet need • No Approved • Products • Designed for long term use • Not absorbed	• Phase 3 Trials Underway (SPA) • Late stage License • Partner engagement underway
VivaGel® BV: Symptomatic Relief (Acute use: 7d)	US$750-1B	• Rapid onset • Good efficacy • Not absorbed • Non antibiotic • Tolerability benefits	• Efficacy at 5-7 days and excellent symptomatic relief • EU approval granted, further submissions • Partner engagement underway

VivaGel® BV
Treatment & Symptomatic Relief of BV

- VivaGel® BV gains EU approval for the treatment and rapid relief of BV
- Allows for marketing in 28 EU countries & EFTA countries (population >260m women)
- EU Approval will be used as the basis for obtaining marketing approvals for VivaGel® BV in other countries
- Discussions regarding marketing rights for VivaGel® BV underway with a number of potential commercial partners
- Current market for the management of BV and associated symptoms is estimated to be in excess of US$750 million globally.



Time to resolution of odour as reported by clinical trial patients

VivaGel® BV is a unique topical vaginal gel. Its proprietary active is not absorbed and acts locally to suppress the pathogens that cause BV and the associated signs and symptoms.

- "It was like gone almost overnight"
- "I would definitely use it again."
- "The next day I noticed a huge difference."
- "I will use it indefinitely…"

VivaGel® BV Trial Participants

VivaGel® BV : Treatment & Symptomatic Relief of BV

Odour Resolution and time to resolution







VivaGel® - 3 Clinical trials

In 3 separate randomised , placebo-controlled trials VivaGel® consistently provided a statistically significantly greater improvement in odour resolution as compared to placebo

Time to resolution of odour, as reported by patients, showed that VivaGel® resolved odour in 1 day, compared to 7 days for placebo

BV Prevention of Recurrence Phase 3 Program
Two double-blind, multi-centre, randomised trials



SPA granted by FDA on trial design (EMA agreement also gained)

Phase 3 Trials progressing well


starpharma
Agrochemicals

The Opportunity for Starpharma's Priostar® Dendrimers in Agrochemicals

The Challenge for Agrochemical Companies

- The cost and risk of registering new agrochemical actives to market is rising.
  ➔ fewer new actives being developed (~70 → 30 between 2000 and 2012)
- ➔ Agrochemical companies have more focus on creating new products with existing actives
- However most formulation components are available to all formulators

Challenge for agrochemical companies…

How to create defendably differentiated products without new actives?

Priostar® benefits for innovative crop protection formulations

Better in the can:

- Solubility enhancement
- Increased loading
- Formulation stability
- Reduction/removal of solvents – "greener" formulations

Better in the field:

- Increased efficacy
- Modification of soil penetration
- Protection of Actives

Starpharma's Patented Priostar® offers…

Improved formulations with high barrier to entry for competitors, with or without new actives

Starpharma's Priostar® Agrochemical Programs

Partnered Priostar® Programs

- **Commercial agreements with many of the leading global agrochemical companies** including **Adama (#7 globally; 2014 sales: ~US$3.2B)**

- Several have now progressed to field trials, with positive interim results
- Anticipate move towards product registration subject to continued positive results
- Priostar® exclusivity offered in a region on a per active basis

  ➔ multiple potential opportunities for revenue streams
- **Estimated value of partners share of market for actives under development: >US$5B**

Internal Priostar® Programs

- SPL is also developing a small number of complete formulations of selected generic actives with enhanced characteristics
- Several programs, including glyphosate, are underway with numerous field trials conducted through the year
- Field trials conducted both domestically and internationally to address different regional weed populations for global coverage
- Internal development candidates include (USD sales 2012):

Glyphosate	($4-5B)	Improve efficacy
Metolachlor	($605M)	Improve efficacy
Deltamethrin	($340M)	Improve efficacy/ remove solvent
Propiconazole	($350M)	Improve efficacy / Loading
Imidacloprid	(>$1B)	Improve efficacy / Loading

Priostar® Dendrimer Glyphosate Formulation – Field Trial Data

More effective in hard-to-kill weeds than comparable marketed formulation



Proposition:

Priostar® offers a unique opportunity to develop **value-added, IP-protected agrochemical formulations with less expense and risk** than new crop-protection actives

- **Dendrimer product more effective in a number of hard-to-kill weeds than comparable marketed glyphosate product**
- 7 regulatory-compliant field trials have now been completed
- Tested in 16 weed species in Australia and overseas

Conclusion: Priostar® formulation performance has consistently exceeded marketed formulations in these field studies.

- Two key benefits identified with Priostar® formulation:
  - **Better overall effectiveness**

    Dendrimer formulation leaves only minimal number of weeds alive at end of study whereas the marketed product had > 30% survival.
  - **Early feedback of effectiveness to grower**

    3 to 4 times as much “brownout” after 5 days than marketed product

Starpharma Holdings – Key Financials (A$)
Strong financial position

Key Financial Data (Financial Year to 30 June)	FY 2015 AUD $M	FY 2014 AUD $M
Total revenue and income	1.7	1.3
R&D Tax Incentive	3.5	4.2
Net loss after tax	(19.0)	(14.6)
Cash outflow from operations	(13.6)	(9.8)
Cash at 30 June	30.8	24.0

Expected Short-Medium Term News Flow

EU Approval Sept. '15

VivaGel® Portfolio:

- Regulatory approvals for BV Symptomatic Relief product
- Commercialisation agreements for BV Symptomatic Relief product
- Progress VivaGel® Phase 3 BV Prevention of Recurrence trials
- Launches of VivaGel® condom, further approvals/geographic roll-out

AZ Licence Sept. '15

DEP™ Drug Delivery:

- Further data/completion DEP™ docetaxel clinical trial (MTD, efficacy signals)
- Partnered program announcements and new deals
- Advance additional DEP™ candidates through preclinical and into clinic

Priostar® Dendrimers in Agrochemicals:

- Advance internal candidates eg. glyphosate (Roundup®) including regulatory-compliant field trials
- Pre-registration activities to support commercialisation
- Partnered program announcements eg. Licences from existing and new deals

For Further Information

Dr Jackie Fairley, CEO
+613 8532 2704
Investor.relations@starpharma.com
Twitter: @Starpharma_ASX

VivaGel®

Drug Delivery

Agrochemicals